---
title: "Eisai and CORE Biomedicine agree on global licence for oncology pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294186150.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-29T07:50:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294186150.md)
  - [en](https://longbridge.com/en/news/294186150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294186150.md)
generator: "portal-rs"
---

# Eisai and CORE Biomedicine agree on global licence for oncology pipeline

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)

## Related News & Research

- [How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings](https://longbridge.com/en/news/292407767.md)
- [Eisai: Strong revenue and profit growth driven by key products and new market launches](https://longbridge.com/en/news/294650708.md)
- [Canon Stock And 2 Japanese Dividend Shares Backed By Steady Cash Flow](https://longbridge.com/en/news/296431213.md)
- [WellSpan and Johns Hopkins renew partnership for advanced cancer care access](https://longbridge.com/en/news/296596329.md)
- [What Eisai (TSE:4523)'s New Long‑Dated Bonds and UK Expansion Means For Shareholders](https://longbridge.com/en/news/289938779.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**